Literature DB >> 10980680

Drug therapy in Behçet's disease.

A A Okada1.   

Abstract

Behçet's disease is one of the most difficult forms of uveitis to treat. Variety in disease presentation and severity, as well as regional differences in standard of care, demand a tailor-made approach. Anterior segment inflammation generally responds to topical corticosteroids. However, the onset of posterior segment inflammation usually requires the advancement of treatment to periocular injections and/or oral administration of corticosteroids. Cyclosporin, either alone or in combination with corticosteroids, is considered in refractory patients. Other immunosuppressive drugs, such as azathioprine and chlorambucil, may be considered in difficult cases. Finally, preliminary results suggest efficacy with the immunomodulatory agent interferon alfa, although further clinical trials are necessary to evaluate safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980680

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  7 in total

Review 1.  Behçet's disease: immunopathologic and therapeutic aspects.

Authors:  Robert Meador; George Ehrlich; Joan M Von Feldt
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

2.  Differential diagnosis of retinal vasculitis.

Authors:  Ahmed M Abu El-Asrar; Carl P Herbort; Khalid F Tabbara
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

3.  Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment.

Authors:  Masaru Takeuchi; Yoko Karasawa; Kohzou Harimoto; Atsushi Tanaka; Masaki Shibata; Tomohito Sato; Rachel R Caspi; Masataka Ito
Journal:  Ocul Immunol Inflamm       Date:  2016-04-12       Impact factor: 3.070

Review 4.  A clinical approach to the diagnosis of retinal vasculitis.

Authors:  Ahmed M Abu El-Asrar; Carl P Herbort; Khalid F Tabbara
Journal:  Int Ophthalmol       Date:  2009-02-04       Impact factor: 2.031

5.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

Review 6.  Update on the diagnosis and management of Behçet's disease.

Authors:  Ryo Rokutanda; Mitsumasa Kishimoto; Masato Okada
Journal:  Open Access Rheumatol       Date:  2014-12-30

7.  Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment

Authors:  Nur Doğanay; Melike Balıkoğlu Yılmaz; Betül Orduyılmaz; Erdinç Aydın; Ali Osman Saatçi
Journal:  Turk J Ophthalmol       Date:  2019-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.